
Valneva is a biotechnology business based in the US. Valneva stocks (INRLF.US) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $13.92 – an increase of 13.39% over the previous week. Valneva employs 719 staff and has a trailing 12-month revenue of around $373 million.
How to buy Valneva stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – INRLF. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Interactive Brokers
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
What's in this guide?
- Can I buy shares in Valneva?
- Has coronavirus impacted Valneva shares?
- Valneva shares summary
- Compare share dealing platforms
- Is Valneva stock a buy or sell?
- Valneva performance over time
- Valneva's financials
- How volatile are Valneva shares?
- Does Valneva pay a dividend?
- Have Valneva shares ever split?
- Other common questions
Valneva stock price (PINK:INRLF)
Use our graph to track the performance of INRLF stocks over time.Valneva shares at a glance
Latest market close | $6.35 |
---|---|
52-week range | $4.69 - $15.75 |
50-day moving average | $5.43 |
200-day moving average | $6.51 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.18 |
Buy Valneva stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Note: The dollar amounts in the table below are in Canadian dollars.
Valneva price performance over time
Historical closes compared with the close of $6.35 from 2023-06-07
1 week (2023-06-01) | 13.39% |
---|---|
1 month (2023-05-09) | 14.21% |
3 months (2023-03-09) | 10.05% |
6 months (2022-12-09) | -13.01% |
1 year (2022-06-09) | -46.28% |
---|---|
2 years (2021-06-09) | -54.51% |
3 years (2020-06-09) | 44.65% |
5 years (2018-06-08) | 42.17% |
Valneva financials
Revenue TTM | $373 million |
---|---|
Gross profit TTM | $-68,060,000 |
Return on assets TTM | -10.21% |
Return on equity TTM | -76.65% |
Profit margin | -36.29% |
Book value | $1.47 |
Market capitalisation | $894.3 million |
TTM: trailing 12 months
Valneva share dividends
We're not expecting Valneva to pay a dividend over the next 12 months.
Have Valneva's shares ever split?
Valneva's shares were split on a 1108:1000 basis on 15 January 2015. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1108 shares. This wouldn't directly have changed the overall worth of your Valneva shares – just the quantity. However, indirectly, the new 9.7% lower share price could have impacted the market appetite for Valneva shares which in turn could have impacted Valneva's share price.
Valneva share price volatility
Over the last 12 months, Valneva's shares have ranged in value from as little as $4.69 up to $15.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Valneva's is 0.9648. This would suggest that Valneva's shares are less volatile than average (for this exchange).
Valneva overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Valneva in the news
VALNEVA - Declaration of shares and voting rights: May 31, 2023
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Valneva Announces the Availability of Documentation for its Shareholder Meeting
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing

How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…More guides on Finder
-
Bad credit loans in Edmonton, Alberta
From personal and payday loans to lines of credit, compare loans for bad credit in Edmonton.
-
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
-
How to buy Pepe (PEPE) in Canada
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
-
How to buy Arbitrum (ARB) in Canada
This guide provides step-by-step instructions on how to buy Arbitrum, lists some exchanges where you can get it and provides daily price data on (ARB).
-
How to buy SSV Network (SSV) in Canada
This guide provides step-by-step instructions on how to buy SSV Network, lists some exchanges where you can get it and provides daily price data on (SSV).
-
How to buy USDD (USDD) in Canada
This guide provides step-by-step instructions on how to buy USDD, lists some exchanges where you can get it and provides daily price data on (USDD).
-
How to buy Blur (BLUR) in Canada
This guide provides step-by-step instructions on how to buy Blur, lists some exchanges where you can get it and provides daily price data on (BLUR).
-
How to buy FLOKI Inu (FLOKI) in Canada
This guide provides step-by-step instructions on how to buy FLOKI Inu, lists some exchanges where you can get it and provides daily price data on (FLOKI).
-
How to buy Aptos (APT) in Canada
This guide provides step-by-step instructions on how to buy Aptos, lists some exchanges where you can get it and provides daily price data on (APT).
-
How to buy EthereumPoW (ETHW) in Canada
This guide provides step-by-step instructions on how to buy EthereumPoW, lists some exchanges where you can get it and provides daily price data on (ETHW).